Recombinant Human Plasma Gelsolin
Phase 2Small molecule
Recombinant Human Plasma Gelsolin is one of 65 small molecule programs targeting Pneumonia. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Primaxin
PfizerPreclinical
Acanya
PfizerPreclinical
Prevacid
TakedaPreclinical
Innohep
Alnylam PharmaceuticalsPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Gantanol
CConrado Roberto Hoffmann Filho
Preclinical
Zantac 150
CChattem
Preclinical
Recombinant Human Plasma Gelsolin
BBioAegis Therapeutics Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Phase 11 trial
Inflammatory Response1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBioAegis Therapeutics Inc.